8th Feb 2022 20:35
GENinCode PLC - Oxford-based biotechnology company focused on risk assessment and prediction of cardiovascular diseases - Hails results from NHS clinical study for Lipid inCode genetic diagnostic test for hypercholesterolemia, meaning high levels of cholesterol. Results of study found Lipid inCode offers same results as standard NHS genetic laboratory testing. "This is expected to increase diagnostic efficiency and support timely clinical management," GENinCode says.
Current stock price: 26.25 pence, down 7.9%
12-month change: down 38%
By Eric Cunha; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Genincode